In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. October 15, 2018

    Opioid MDL Needs Gov't Docs To Advance, Drugmakers Say

    Opioid makers and pharmacies on Monday backed a special master's ruling that requires local governments suing drugmakers in multidistrict litigation over the opioid epidemic to identify hundreds of prescriptions, saying that so far they've borne the brunt of coughing up discovery information.

  2. October 09, 2018

    Opioid MDL Gov'ts Must Pinpoint Improper Prescriptions

    Local governments suing drugmakers in multidistrict litigation over the opioid epidemic must identify hundreds of prescriptions allegedly influenced by dishonest marketing and describe specific patients who became addicted to painkillers, according to a new ruling that appears likely to prove contentious. 

  3. October 09, 2018

    450 Tribes Demand A 'Seat At The Table' In Opioid MDL

    Nearly 450 Native American and Alaskan Native tribes have collectively told an Ohio federal court why it is vital to have their own voice in multidistrict litigation tied to the opioid crisis, detailing a history of oppression by states, limited access to resources, and disproportionately high drug addiction and death rates.

  4. October 05, 2018

    Ohio County's Opioid Bellwether Gets OK From Magistrate

    An Ohio magistrate federal judge on Friday largely sided with an Ohio county bringing one of the bellwether suits in the massive opioid multidistrict litigation and recommended against tossing the bulk of its claims that pharmacies, opioid manufacturers and distributors fueled the opioid crisis.

  5. September 24, 2018

    Allergan's Discovery Buck-Passing Rejected In Opioid MDL

    Allergan PLC can't avoid coughing up documents about its sales of narcotic painkillers even though Teva Pharmaceutical Industries Ltd. recently acquired the painkillers' rights and legal liabilities, according to a new ruling in multidistrict litigation over the opioid epidemic.

  6. September 20, 2018

    New MDL Needed For 'Opioid Babies,' Attys Say

    Attorneys for "opioid babies" whose mothers used prescription narcotics argued on Thursday for new multidistrict litigation focused on the infants, citing "grave concerns" that an existing MDL over the opioid crisis is woefully deficient.

  7. September 17, 2018

    Opioid MDL Stakes Rise For Pharmacy Benefit Cos.

    The nation's biggest pharmacy benefit management companies should be forced to clamp down on painkiller prescriptions, according to a new motion that raises the stakes for PBMs in multidistrict litigation over the opioid epidemic and contains fresh signs of friction among plaintiffs attorneys.

  8. September 05, 2018

    Tribes Can't Have Opioid Suits Sent To State Court From MDL

    An Ohio federal judge rejected bids by two tribes to remand to state court their suits against McKesson Corp. and other companies over the opioid crisis, ruling that the claims belong in federal court because McKesson was subject to federal control under a government contract when it allegedly allowed the drugs to be diverted.

  9. September 04, 2018

    Tribe Can't Fault Generics Cos. For Opioid Crisis, Court Told

    A group of generic-drug makers pushed back at a Montana tribe's attempt in multidistrict litigation ongoing in Ohio federal court to hold them liable for the opioid epidemic, saying they shouldn't be lumped in with their brand-name counterparts because they operate under a different business model.

  10. August 31, 2018

    Pharma Cases To Watch In 2018's Home Stretch

    Drugmakers in the closing months of 2018 may see pivotal rulings on novel efforts to hamstring rival medicines, escalating drama in multidistrict litigation over the opioid epidemic, and opening salvos in False Claims Act and drug-pricing fights at the U.S. Supreme Court. Here, Law360 summarizes key cases to watch.